Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Deferred Taxes (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Deferred Taxes for 16 consecutive years, with $100000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Deferred Taxes fell 50.0% to $100000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.1 million, a 60.71% increase, with the full-year FY2025 number at $100000.0, up 103.57% from a year prior.
  • Deferred Taxes was $100000.0 for Q4 2025 at Myriad Genetics, down from $200000.0 in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $600000.0 in Q1 2024 to a low of -$16.3 million in Q3 2021.
  • A 5-year average of -$4.1 million and a median of -$2.2 million in 2024 define the central range for Deferred Taxes.
  • Peak YoY movement for Deferred Taxes: plummeted 1666.67% in 2022, then surged 500.0% in 2024.
  • Myriad Genetics' Deferred Taxes stood at -$4.3 million in 2021, then tumbled by 104.65% to -$8.8 million in 2022, then soared by 73.86% to -$2.3 million in 2023, then soared by 108.7% to $200000.0 in 2024, then plummeted by 50.0% to $100000.0 in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Deferred Taxes are $100000.0 (Q4 2025), $200000.0 (Q4 2024), and -$1.4 million (Q3 2024).